FAM183BP

Across TCGA pan-cancer cohorts, FAM183BP Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated FAM183BP data layer compared with 25 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FAM183BP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM183BP expression acts as an unfavorable survival marker.

ACC, BLCA, and LIHC are the cancer types where FAM183BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
BLCA	OS	Median	All	0.069	0.688	<.001	24	view →
LIHC	OS	Median	All	0.071	0.779	<.001	21	view →
THCA	DFS	Median	All	0.062	0.909	<.001	12	view →
SARC	DFS	Median	All	0.101	0.632	.011	6	view →
SKCM	DFS	Median	III,IV	0.041	0.665	<.001	5	view →
PRAD	DFS	Median	All	0.205	0.779	.001	4	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	3	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

FAM183BP–ACC (DFS)

Open the ACC breakdown →